Artemisia annua. A. apiacea 青 蒿  Qīng hāo   Sweet wormwood, Sweet sagewood   Family: Asteraceae   
In some parts of China A. apiacea is used as this herb.
PART USED: Above ground- harvested in Summer before the flowers bloom.
Nature: Cold     FLAVOR: Bitter, pungent, fragrant   CHANNEL: Liver, Gall bladder, Kidney
FUNCTIONS
GROUP: Clearing Internal Heat- Clear Summer Heat- Clearing empty Heat.
1. Clear Summer Heat; especially with low fever, headache, dizziness, and a stifling sensation in the chest.[5] Clear Heat. Clears fevers.[1]  Detoxifies.[1] Cools Heat by inducing perspiration (but not effectively during a high fever), stops summer time nose bleeding. Childrens fevers.[6]
2. Clear deficiency fever.[5]
3. Cools Blood and stops bleeding.[5]
4. Clears away Heat from the Gall bladder, preventing the recurrence of malaria.[5]
5. Exerts vermicidal action, tonifies the Stomach.[1]
ACTIONS
INDICATIONS
1. Deficient fevers at the later stage with an accumulation of Heat in the Yin system or blood deficiency; nocturnal fever, or unremitting fever and morning coolness with an absence of sweating.[5] Thirst, hydrosis in chronic fevers, frequent bloody urination.[1] Bone Steaming fever:[4] Tidal fever, night fever, feverish sensation in the palms and soles due to Yin deficiency.
2. Malaria with alternate fevers and chills.[5] Jaundice.[1]
3. Summer Heat; low fever with or without sweating, dizziness and headache, stifling sensation in the chest.[5] Infantile fever.
4. Vomiting and diarrhea, abdominal pain, abdominal distension.[5]
4. Acute and chronic convulsive attacks.[1]
5. Skin diseases.[1] Purpuric rashes or nosebleed dut to Heat in the Blood.[5]
CONTRAINDICATIONS: Spleen/Stomach deficiency, excessive sweating and diarrhea.[4] Postpartum women with Blood deficiency, or in cases of Cold from Spleen and Stomach deficiency.[5]
PATENT COMBINATIONS
COMBINATIONS
PREPARATIONS: Decoction. Above ground 4-10 g.[2,3,4,5] For a stronger Heat clearing effect, up to 24 g may be used.[5] Should not be decocted for long.[5] The leaves are the most potent part of the plant.[5] Good quality is yong, green, and fragrant.
Note- This drug should not be decocted over a long period of time.[3]
15-30 g.[1]
Concentration standard- Arteannuin.
   
PART USED: Seeds
INDICATIONS
1. Consumption, flatulence, dyspepsia, night sweats, and to destroy noxious vapors.[6]

HABITAT: Found growing in waste places, field edges and roadsides.
DESCRIPTION
References
Inner Path can not take any responsibility for any adverse effects from the use of plants. Always seek advice from a professional before using a plant medicinally.
Constituents
Research

An extract of the medicinal plant Artemisia annua modulates production of inflammatory markers in activated neutrophils
Sheena Hunt, Mayumi Yoshida, Catherine EJ Davis, Nicholas S Greenhill, and Paul F Davis
Abstract
Purpose
To investigate the ability of a commercial extract from the medicinal plant Artemisia annua to modulate production of the cytokine, tumor necrosis factor-alpha (TNF-α), and the cyclooxygenase (COX) inflammatory marker, prostaglandin E2 (PGE2) in activated neutrophils.
Methods
Neutrophils were harvested from rat whole blood and cultured in the presence of plant extract or control samples. Neutrophils, except unactivated control cells, were activated with 10 μg/mL lipopolysaccharide (LPS). The cells were cultured with a range of different concentrations of the A. annua extracts (400–1 μg/mL) and artemisinin (200 and 100 μg/mL) and the supernatants were then tested by enzyme-linked immunosorbent assay (ELISA) for the concentrations of TNF-α and PGE2. Each sample was assayed in triplicate. Positive controls with an inhibitor were assayed in triplicate: chloroquine 2.58 and 5.16 μg/mL for TNF-α, and ibuprofen 400 μg/mL for PGE2. An unsupplemented group was also assessed in triplicate as a baseline control.
Results
Neutrophils were stimulated to an inflammatory state by the addition of LPS. A. annua extract significantly inhibited TNF-α production by activated neutrophils in a dose-dependent manner. There was complete inhibition by the A. annua extract at 200, 100, and 50 μg/mL (all P≤0.0003). At A. annua extract concentrations of 25, 10, and 5 μg/mL, TNF-α production was inhibited by 89% (P<0.0001), 54% (P=0.0002), and 38% (P=0.0014), respectively. A. annua 1 μg/mL did not significantly inhibit TNF-α production (8.8%; P>0.05). Concentrations of 400, 200, and 100 μg/mL A. annua extract significantly inhibited PGE2 production by 87% (P=0.0128), 91% (P=0.0017), and 93% (P=0.0114), respectively.
Conclusion
An extract of A. annua was shown to be a potent inhibitor of TNF-α and a strong inhibitor of PGE2 production in activated neutrophils at the concentrations tested. Further studies are warranted with this promising plant extract.
J Inflamm Res. 2015; 8: 9–14.
Published online 2015 Jan 14. doi: [10.2147/JIR.S75484]
PMCID: PMC4298291
PMID: 25609991 ncbi.nlm.nih.gov

Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial.
Munyangi J, et al. Phytomedicine. 2018.
Abstract
BACKGROUND AND OBJECTIVE: Schistosomiasis (bilharzia), a serious neglected tropical disease affecting millions, has few cost-effective treatments, so two Artemisia wormwood species, A. annua and A. afra, were compared with the current standard praziquantel (PZQ) treatment in an 800 patient clinical trial, August-November of 2015.
METHODS: The double blind, randomized, superiority clinical trial had three treatment arms: 400 for PZQ, 200 for A. annua, and 200 for A. afra. PZQ-treated patients followed manufacturer posology. Artemisia-treated patients received 1 l/d of dry leaf/twig tea infusions divided into 3 aliquots daily, for 7 days with 28-day follow-up.
RESULTS: Of 800 enrolled patients having an average of >700 Schistosoma mansoni eggs per fecal sample, 780 completed the trial. Within 14 days of treatment, all Artemisia-treated patients had no detectable eggs in fecal smears, a result sustained 28 days post treatment. Eggs in fecal smears of PZQ-treated patients were undetectable after D21. More males than females who entered the trial had melena, but both genders responded equally well to treatment; by D28 melena disappeared in all patients. In all arms, eosinophil levels declined by about 27% from D0 to D28. From D0 to D28 hemoglobin increases were greater in PZQ and A. afra-treated patients than in A. annua-treated patients. Hematocrit increases were greater from D0 to D28 for patients treated with either PZQ or A. annua compared to those treated with A. afra. Gender comparison showed that A. afra-treated males had significantly greater hemoglobin and hematocrit increases by D28 than either PZQ or A. annua-treated males. In contrast, PZQ and A. afra-treated females had greater hemoglobin and hematocrit increases than A. annua-treated females. Both adults and pediatric patients treated with A. annua responded better compared to PZQ treatment.
CONCLUSION: Both A. annua and A. afra provided faster effective treatment of schistosomiasis and should be considered for implementation on a global scale.
PMID 30466622 ncbi.nlm.nih.gov